Pathfinder Arrives in MapleStory M’s December Update
17.12.2021 01:03:00 EET | Business Wire | Press release
MapleStory M, Nexon’s popular free-to-play mobile MMORPG, has officially launched its latest update, bringing the long-awaited Pathfinder class to the game alongside a flurry of winter season events and activities for Maplers to tackle. The Pathfinder update has also increased the max level to 250, and brings new daily and weekly missions, achievements, and a new mini-dungeon to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006140/en/
Pathfinder Arrives in MapleStory M’s December Update (Graphic: Business Wire)
As of today, the sharpshooting Explorer who wields an ancient bow, Pathfinder, is available as a new playable class. Maplers who pre-registered their Pathfinder were eligible for items such as Auto Battle Charge Tickets and EXP tickets, while all players can take part in Mega Burning and On-Time/Growth Support events to help level-up a new Pathfinder quickly. As a bonus after today’s maintenance, both MapleStory M and MapleStory will be running the Pathfinder Link Event through January 19, 2022, whereby, after reaching level, 70, 120, and 140 on MapleStory M with the Pathfinder, Maplers can garner rewards in both games, including a Pathfinder outfit gift box, Ancient Relic, and more.
The Black Mage's fourth commander, Arkarium, formerly a servant under Rhinne, Maple World's Transcendent of Time, makes his debut in MapleStory M. Maplers will be able to craft all-new boss accessory Dominator Pendant using the materials acquired when defeating Arkarium.
A new map in the Arcane River has also been added, the Dreaming City Lachelein, bringing with it new quests, monsters, area items to discover, and a new Arcane force field. Mini-dungeons have also received a quality of life improvement with this update so that Maplers can auto-play multiple times by using tickets and mesos.
In addition to the events celebrating the arrival of Pathfinder, players can look forward to numerous winter seasonal events occurring throughout December and into the new year:
- I&B Burning Challenge Mission Event - From December 15, 2021 through January 19, 2022, this event returns, granting not only Ice Agent or Burning Agent player titles, but also granting daily missions for players to conquer.
- Holiday Mr. Kim’s Gift - From December 22 through December 30, 2021, tapping on Mr. Kim will reward players with special items.
-
Winter Happyville
Events - (Various scheduled times - refer to in-game event banner or see MapleStoryM patch notes for exact times and dates for each event.) Winter Happy Village will play host to multiple winter events throughout December and January :
- Coin Drop Event
- A Well-Behaved Child Needs A Gift!
- A Crying Child Also Needs A Gift!
- Buff Tree Event
- Great Rudolph Escape
- 2022 Countdown Event - From December 23, 2021 through January 6, 2022, players can enter the event map every day and receive EXP for ten minutes. After spending ten minutes on the map, these players will receive a countdown reward and, on January 1, Maplers can earn a special New Year reward!
- Snowflake Snowpark - From January 6 through January 18, 2022, Maplers can earn AB tickets, EXP tickets, and Gold Leaf by clearing different missions and receiving stamps.
- 2022 New Year Wheel - From January 13 through January 27, 2022, players can receive a maximum of 5 wheel tickets per day by hunting. Rewards for participating in the event include AB tickets, Luckyday scroll 5%, cubes, EXP tickets, and more.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006140/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
